核药物发展小记
|
|
李聪,刘慧,韩宇翔,刘志博
|
Nuclear Medicine: The Synergy of Radiochemistry and Molecular Medicine
|
|
Cong LI,Hui LIU,Yuxiang HAN,Zhibo LIU
|
|
| 表1 64Cu相关分子探针 |
| |
|
| Cu同位素标记的PET探针 | 探针功能 | | 64Cu-CPTA-D-Phe1-奥曲肽 | 生长抑素受体[14] | | 64Cu-TETA-D-Phe1-奥曲肽 | 生长抑素受体[14] | | 64Cu(67Cu)-BAT-21T-1A3 | 放射性免疫治疗[15] | | 64Cu-DOTA-mPEG | 体内组织成像[16] | | 64Cu-labeled SCK1–4 | 体内组织成像[16] | | 64Cu-二乙酰二(N4-甲基氨基硫脲) | 乏氧组织[17] | | 64Cu-ATSM | 乏氧组织[17] | | 64Cu-DOTA-Aoc-BN | GRPR阳性肿瘤[18] | | 60Cu-二乙酰二(N4-甲基氨基硫脲) | 宫颈癌[19] | | 64Cu-DOTA-CANF | 血管新生[20] | | 64Cu-DOTA-CANF-comb | 血管新生[20] | | 64Cu-DOTA-comb | 血管新生[20] |
|
|
|